JAIDS Journal of Acquired Immune Deficiency Syndromes,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Nov. 21, 2023
Abstract:
Background:
Physical
activity
(PA)
regulates
intrahepatic
storage
of
fat
and
reduces
the
risk
liver
steatosis.
Given
our
limited
understanding
pathogenesis
metabolic
complications
in
people
with
HIV
(PWH),
it
remains
unclear
if
evidence
from
general
population
can
be
extrapolated
to
PWH.
We
investigated
association
between
PA
steatosis
a
single
site
Swiss
Cohort
Study
(SHCS).
Methods:
screened
consecutive
SHCS
participants
using
vibration
controlled
transient
elastography
defined
as
CAP
≥248dB/m.
was
measured
International
Activity
Questionnaire.
evaluated
three
different
measures
separate
multivariable
logistic
regression
models.
Results:
Of
466
participants,
127
(27.3%)
were
female,
median
age
52
years
(interquartile
range
43-59)
244
(52.4%)
overweight
(BMI
≥25
kg/m
2
).
Liver
present
235
(50.4%)
individuals.
In
analysis,
below
recommendations
European
Association
for
associated
(adjusted
odds
ratio
(aOR),
2.34;
95%
confidence
interval
(CI),
1.44-3.85).
Using
alternative
scales
PA,
including
equivalents
task
(MET)
minutes
(min)
per
week
(aOR
0.76,
CI
0.60-0.94)
sitting
hours
day
(aOR,
1.16;
1.07-1.26),
yielded
comparable
results
associations
similar
when
we
restricted
analyses
lean
(BMI<25
)
subjects.
Conclusion:
Insufficient
prolonged
time
both
among
PWH,
independent
BMI.
Our
support
importance
promoting
prevent
Clinical Infectious Diseases,
Journal Year:
2023,
Volume and Issue:
77(12), P. 1687 - 1695
Published: July 21, 2023
Abstract
Background
We
investigated
the
association
between
nonalcoholic
fatty
liver
disease
(NAFLD)
plus
or
minus
a
concurrent
diagnosis
of
steatohepatitis
(NASH)
and
incident
diabetes
mellitus
(DM)
risk
factors
associated
with
NAFLD
NASH
development.
Methods
In
this
prospective
study,
we
analyzed
people
human
immunodeficiency
virus
(HIV;
PWH)
aged
≥18
years
without
excessive
alcohol
consumption
hepatitis
coinfections.
was
defined
as
controlled
attenuation
parameter
≥248
dB/m,
whereas
significant
activity
fibrosis
FibroScan-AST
score
≥0.67.
Cox
proportional
hazard
regression
used
to
investigate
new-onset
DM.
Results
Of
847
PWH,
median
age
at
baseline
45
(interquartile
range,
38–51;
43%
female).
Baseline
2.8-fold
higher
DM
after
adjusting
for
age,
sex,
family
history
DM,
antiretroviral
therapy
duration,
smoking,
statin
use,
stavudine/didanosine/zidovudine
exposure,
time-updated
body
mass
index,
hypertension,
dyslipidemia.
Combined
had
3.1-fold
risk.
separate
analyses,
did
not
predict
progression
NASH,
but
tenofovir
alafenamide
use
an
increased
(hazard
ratio
[HR],
2.01;
95%
confidence
interval
[CI],
1.02–4.02)
development
(2.31;
CI,
1.12–5.11).
Conclusions
alone
combined
strongly
predicts
This
highlights
need
systematic
assessments
management
NAFLD/NASH,
it
may
contribute
metabolic
complications
such
subsequent
cardiovascular
diseases
in
PWH.
Frontiers in Public Health,
Journal Year:
2024,
Volume and Issue:
11
Published: Jan. 4, 2024
Europe
faces
an
elevated
risk
of
nonalcoholic
fatty
liver
disease
(NAFLD)
among
people
living
with
HIV
(PLWH),
contributing
to
the
region's
highest
global
burden
NAFLD.
However,
prevalence
NAFLD
across
various
European
countries
and
regions
remains
unclear.
This
study
aims
investigate
factors
associated
PLWH
countries.
Open Forum Infectious Diseases,
Journal Year:
2024,
Volume and Issue:
11(6)
Published: May 7, 2024
Abstract
Background
Steatotic
liver
disease
is
suggested
to
have
a
higher
prevalence
and
severity
in
people
with
HIV
(PHIV),
including
those
normal
body
mass
index
(BMI).
In
this
study,
we
used
data
from
the
2000HIV
cohort
(1)
assess
of
steatosis
fibrosis
lean
versus
overweight/obese
PHIV
(2)
associations
these
subgroups
between
traditional
risk
factors
HIV-specific
characteristics.
Methods
The
study
comprises
1895
virally
suppressed
that
were
included
2019
2021
4
treatment
centers
Netherlands.
majority
(58.5%)
underwent
vibration-controlled
transient
elastography
for
assessment
fibrosis.
(controlled
attenuation
parameter
≥263
dB/m)
(liver
stiffness
measurement
≥7.0
kPa)
was
estimated.
Multiple
characteristics
antiretroviral
drugs
tested
logistic
regression
model
association
Analyses
performed
separately
(Asian
descent:
BMI
<
23
kg/m2,
other
25
kg/m2)
(other
BMI)
participants.
Results
Of
1050
505
545
PHIV,
observed
37.7%
overall
population,
19.7%
lean,
54%
whereas
9.0%
5.9%
12.0%
PHIV.
All
most
concerned
metabolic
such
as
type
2
diabetes
mellitus
(overall
population:
adjusted
odds
ratio
[aOR]
steatosis:
2.3
[1.21-4.4],
P
=
.011;
aOR
fibrosis:
3.7
[1.82-7.53],
.001).
Furthermore,
PLHIV,
associated
CD4
CD8
counts
at
enrollment,
dual
therapy,
history
raltegravir
(aOR:
3.6
[1.53-8.47],
.003),
stavudine
3.73
[1.69-8.2],
.001),
indinavir
3.86
[1.59-9.37],
.003).
These
not
Conclusions
Liver
highly
prevalent,
affecting
approximately
one-fifth
half
Fibrosis
minority.
Both
factors.
addition,
(prior)
exposure
specific
but
Implementing
increased
screening
protocols
could
enhance
identification
steatotic
Clinical Infectious Diseases,
Journal Year:
2023,
Volume and Issue:
77(7), P. 1012 - 1020
Published: June 20, 2023
Abstract
Background
Starting
combination
antiretroviral
therapy
(cART)
during
primary
human
immunodeficiency
virus
type
1
(HIV-1)
infection
results
in
a
smaller
HIV-1
latent
reservoir,
reduced
immune
activation,
and
less
viral
diversity
compared
to
starting
cART
chronic
infection.
We
report
of
4-year
study
designed
determine
whether
these
properties
would
allow
sustained
virological
suppression
after
simplification
dolutegravir
(DTG)
monotherapy.
Methods
EARLY-SIMPLIFIED
is
randomized,
open-label,
noninferiority
trial.
People
with
HIV
(PWH)
who
started
<180
days
documented
suppressed
load
were
randomized
(2:1)
DTG
monotherapy
50
mg
daily
or
continuation
cART.
The
endpoints
the
proportion
PWH
failure
at
48,
96,
144,
192
weeks;
margin
was
10%.
After
96
weeks,
randomization
lifted
patients
permitted
switch
treatment
groups
as
desired.
Results
Of
101
68
assigned
33
At
week
per-protocol
population,
64/64
(100%)
showed
response
group
versus
30/30
(difference,
0.00%;
upper
bound
95%
confidence
interval
6.22%).
This
demonstrated
prespecified
level.
192,
end,
no
occurred
either
13
308
4897
person
weeks
follow-up
for
(n
=
80)
groups,
respectively.
Conclusions
trial
suggests
that
early
initiation
allows
switching
Viruses,
Journal Year:
2023,
Volume and Issue:
15(12), P. 2432 - 2432
Published: Dec. 15, 2023
In
the
last
three
decades,
there
has
been
a
considerable
improvement
in
human
immunodeficiency
virus
(HIV)
therapy.
Acquired
syndrome
(AIDS)
is
no
longer
common
cause
of
death
for
people
living
with
HIV
(PLWH)
developed
countries,
and
co-infections
hepatitis
viruses
can
be
effectively
managed.
However,
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
are
emerging
threats
these
days,
especially
as
HIV-positive
population
gets
older.
The
factors
MASLD
development
PLWH
numerous,
including
non-specific
(common
both
negative)
virus-specific.
We
focus
on
what
known
both,
particular,
burden
antiretroviral
therapy
(ART)
health
damage.
review
data
contemporary
drugs,
different
groups
some
particular
agents
those
groups.
Among
current
ART
regimens,
switch
from
tenofovir
disoproxil
fumarate
(TDF)
to
alafenamide
(TAF)
particularly
its
combination
integrase
inhibitors
(INSTIs)
appear
have
most
significant
impact
disturbances
by
increasing
insulin
resistance,
which
over
years
promotes
evolution
cascade
leading
(MetS),
MASLD,
eventually
steatohepatitis
(MASH).
HIV Research & Clinical Practice,
Journal Year:
2024,
Volume and Issue:
25(1)
Published: June 3, 2024
Weight
gain
has
been
well-described
with
integrase
strand
transfer
inhibitors
(INSTIs)
and
tenofovir
alafenamide
(TAF).
Doravirine
(DOR)
identified
as
a
relatively
"weight-neutral"
drug;
however,
there
is
little
data
describing
its
effect
on
weight
change
in
routine
clinical
practice.
Metabolic Syndrome and Related Disorders,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 19, 2025
Background:
The
prevalence
of
fatty
liver
disease
in
people
living
with
human
immunodeficiency
virus
(PLHIV)
is
significantly
higher
than
general
population.
This
study
aims
to
compare
the
burden
Egyptian
PLHIV
using
both
metabolic
dysfunction-associated
(MAFLD)
and
steatotic
(SLD)
criteria.
Methods:
A
retrospective
cross-sectional
was
conducted
on
attending
HIV
reference
center
at
Embaba
Fever
Hospital
Egypt
between
November
2019
July
2021.
Data
collection
included
demographics,
comorbidities,
physical
examination,
laboratory
tests,
ultrasound,
controlled
attenuation
parameter,
stiffness
measurement
Fibroscan®.
Results:
SLD
MAFLD
26.92%
21.15%,
respectively.
concordance
definitions
low
(kappa
=
0.465).
presence
associated
increased
odds
significant
fibrosis
(P
0.045).
However,
not
0.369).
Conclusion:
demonstrates
a
stronger
association
PLHIV.
highlights
potential
as
more
inclusive
representative
classification
for
steatosis
